Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.50, read 2026-11-05
Ethical screen not yet scored
Price14.80 USD
Fair value7.40
Ethical score70.0/100
Value readOvervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-11-04Read Distribution15.23-2.8% to today ✓Markup gives way to Distribution after a 12% rise in 7 days
2026-10-28Read Markup13.60+8.8% to today ✓Distribution gives way to Markup after an 18% slide in 4 weeks
2026-10-02Read Distribution16.53-10.5% to today ✓Markup gives way to Distribution after a 695% rise in 7 weeks
2026-08-11Read Markup2.08+611.5% to today ✓Distribution gives way to Markup after a 28% rise in 6 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The Real Brokerage Inc holds its Markup at $14.80. The statistical read favours the sellers, held for 26 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 26 days
Price at the screen
$14.80
Valuation
N/A trailing · -52.00 forward price to earnings
Values screen
Not scored· score 70.0
Beta
0.74
The Workings
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
13.19%
Below 33%
Cash held in interest-bearing accounts and securities is 13.2% of assets, under the one-third limit.
Pass
Receivables
42.08%
Below 49%
Money owed to the company is 42.1% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
The Read, in Plain English
The Real Brokerage clears the business-activity screen and the figures we can measure look clean, but its debt figure is still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 5 Nov 2026: it trades above our $7.40 fair value estimate, none competitive moat, 31.50% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 100.0% above the base estimate.
Where our models see it going: fair-value estimate $7.40, range not available, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At -52.0x forward earnings, the price already runs ahead of the business. It trades 100% above our $7.40 fair value, so you would be buying at a premium, not a discount. The none moat is real, but quality alone does not make an expensive price cheap.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
REAX trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 12.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (5 analysts) rates it none, with a mean price target of $5.
2026-10-28Markup · changed$13.60+0.0%Entry 9
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (5 analysts) rates it none, with a mean price target of $5.
2026-10-21Distribution$13.60-13.1%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 13.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (5 analysts) rates it none, with a mean price target of $5.
2026-10-14Distribution$15.65-5.3%Entry 7
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (5 analysts) rates it none, with a mean price target of $5.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 694.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (5 analysts) rates it none, with a mean price target of $5.
2026-09-11Markup$2.08+0.0%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (5 analysts) rates it none, with a mean price target of $5.
2026-08-11Markup · changed$2.08+28.4%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 28.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (5 analysts) rates it none, with a mean price target of $5.
2026-07-18Distribution$1.62+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (5 analysts) rates it none, with a mean price target of $5.
2026-07-03Distribution$1.62+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$1.62Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.